PREDICTORS OF ONE-YEAR VISUAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Authors:
- for the GEFAL Study GroupFGfor the GEFAL Study Group
- 1 August 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 38 (8) , 1492-1499
Abstract
Purpose: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular age-related macular degeneration (GEFAL). Methods: Patients aged ≥50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen). The main outcome measures were BCVA and its change from baseline at 1 year. Variables with a P value μm, predominantly classic choroidal neovascularization, and total area of choroidal neovascularization (all P ≤ 0.01). Pigment epithelium detachment and high baseline BCVA were associated with less improvement in BCVA (P = 0.03, P = 0.05, respectively). Patients who met retreatment criteria but did not receive the corresponding injection had significantly poorer outcomes (only tested in the univariate analysis). Conclusion: This study confirms the predictors of BCVA score at 1 year posttreatment; the presence of intraretinal fluid was associated with a poor prognosis.Keywords
This publication has 27 references indexed in Scilit:
- A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2013
- Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010American Journal of Ophthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical TrialsOphthalmology, 2011
- Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional settingBritish Journal of Ophthalmology, 2009
- Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degenerationEye, 2009
- One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroupsJapanese Journal of Ophthalmology, 2009
- Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR ResultsAmerican Journal of Ophthalmology, 2007
- CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHYRetina, 2003
- NATURAL HISTORY OF SUBFOVEAL SUBRETINAL HEMORRHAGE IN AGERELATED MACULAR DEGENERATIONRetina, 1996